You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 9,079,928

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,079,928 protect, and when does it expire?

Patent 9,079,928 protects AZSTARYS and is included in one NDA.

This patent has fifty-four patent family members in twenty-eight countries.

Summary for Patent: 9,079,928

Scope and claims summary:

Title:	Methylphenidate-oxoacid conjugates, processes of making and using the same
Abstract:	The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.
Inventor(s):	Guenther; Sven (Coralville, IA), Chi; Guochen (Coralville, IA), Bera; Bindu (Blacksburgh, VA), Mickle; Travis (Coralville, IA), Bera; Sanjib (Blacksburg, VA)
Assignee:	KemPharm, Inc. (Coralville, IA)
Application Number:	14/234,440
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,079,928

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-001	May 7, 2021		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-002	May 7, 2021		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-003	May 7, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,079,928

PCT Information
PCT Filed	July 27, 2012	PCT Application Number:	PCT/US2012/048641
PCT Publication Date:	January 31, 2013	PCT Publication Number:	WO2013/016668

International Family Members for US Patent 9,079,928

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	087390	⤷ Subscribe
Australia	2012286683	⤷ Subscribe
Brazil	112014002084	⤷ Subscribe
Canada	2837732	⤷ Subscribe
Canada	2984544	⤷ Subscribe
Canada	3123900	⤷ Subscribe
Chile	2014000210	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.